Waiblingen, Germany/Minneapolis, USA, April 9, 2024. Syntegon today announced the sale of its newly developed Versynta microBatch production cell to its first U.S. customer. Kindeva Drug Delivery will use Versynta microBatch to further expand its suite of aseptic fill-finish contract development and manufacturing (CDMO) capabilities meeting the latest global pharmaceutical regulations and trends. Kindeva is a leading global CDMO that develops and manufactures products across a range of routes of administration including injectable, pulmonary, nasal, transdermal, and intradermal delivery.
Robotic competence on the smallest scale
“Syntegon’s Versynta microBatch enables Kindeva to offer significant flexibility to our customers by rapidly adding clinical development and small-scale commercial GMP filling capacity, which complements our large-scale vial, syringe, and cartridge isolator filling lines. Syntegon’s technology expertise is unquestionable, but it is their ability to partner that has really made this an ideal collaboration for Kindeva,” said David Stevens, Kindeva Global Chief Commercial Officer. “Versynta microBatch provides agility, best-in-class automation, and sterility assurance that meets our patient safety and regulatory compliance objectives which we believe sets the standard for CDMOs.”
The fully automated production cell is specifically designed for very small batches of highly potent and often highly costly drugs, for instance in the field of cell and gene therapy, where maximum product yields are key. Versynta microBatch fills between 120 and 500 syringes, cartridges, and vials made of glass or plastic per hour with virtually no product loss. Fast batch-to-batch changeovers ensure that efficiency remains high without compromising on flexibility.
Prepared for regulatory challenges
As Kindeva serves a global client base, compliance with local regulations of its target markets is paramount. For Europe, this includes the new EU GMP Annex 1, which is setting new benchmarks in aseptic fill-finish operations. Syntegon developed Versynta microBatch with these requirements in mind: the gloveless isolator with integrated air treatment significantly reduces operator intervention and the risk of contamination. The 100 percent in-process control ensures high quality. Five integrated inline inspection systems provide special safety, while optional network cameras ensure continuous monitoring of production in the isolator via remote access.
“During my 35 years of working in the pharmaceutical packaging and processing business, it is rare to experience the partnership Syntegon and Kindeva enjoy. With our joint successes, their experience, and high level of technical capabilities, Kindeva is a perfect partner for our technology-leading Versynta microBatch,” said Kerry Fillmore, Managing Director of Syntegon Pharma Technology in North America.
Join the microBatch experience at INTERPHEX
Visitors to INTERPHEX can experience the potential of Versynta microBatch first-hand. Syntegon will offer an immersive experience covering small and microBatch filling as well as ready-to-use (RTU) trends.
Visit Syntegon and Kindeva at INTERPHEX, April 16-18, 2024, at Booths 1719 and 1147, respectively.
About Syntegon
Processing and packaging for a better life – this is what 5,800 Syntegon employees work for every day. Be it with individual machines, systems, or services, Syntegon helps its customers in the global pharmaceutical and food industries to improve people’s lives. The company, which is headquartered in Waiblingen, Germany, looks back on more than 160 years of experience and achieved annual sales of 1.4 billion EUR in 2022. In the pharma sector, the company’s intelligent solutions enable the safe and high-quality production, processing, filling, inspection, and packaging of liquid and solid pharmaceuticals. In the food industry, Syntegon’s flexible and reliable technologies produce and pack confectionery, dry food, frozen food, and dairy products. With 1,100 service experts and a comprehensive service portfolio throughout the entire machine lifecycle from spare parts management to digital line optimization, Syntegon lays the foundation for smooth production processes for all customers. More than 35 sites in almost 20 countries keep a firm eye on Syntegon’s impact on the environment and society. Syntegon is a leader in the development of sustainable packaging solutions, reduces the energy consumption of its machines and pursues ambitious goals to lower its emissions. www.syntegon.com.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Kindeva’s service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from its state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
Contact
Nicole König
Spokesperson Product Communications Pharma
+49 7951 402-648
nicole.koenig@syntegon.com
Related news
Explore more of our latest news and announcements, where the demands of today meet the possibilities of tomorrow.
Kindeva Drug Delivery awarded up to $129 million to supply DuoDote® autoinjectors to the Strategic National Stockpile
ST. LOUIS, Mo. and WOODBURY, Minn: 16th Jan 2025 (Business Wire) – Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies, LLC, secured a contract valued at up to $129 million to supply DuoDote®, a chemical nerve agent antidote autoinjector, to the Strategic National Stockpile (SNS), managed by the Administration for Strategic Preparedness and […]
Learn MoreKindeva Drug Delivery and Emervax partner to bring game changing vaccine administration to patients
Woodbury, Minnesota and Houston, Texas – JAN 09, 2025: Kindeva Drug Delivery, a global CDMO and drug delivery expert, and Emervax, a developer of a proprietary circular RNA-based vaccine platform (emxRNATM), today announced an exclusive partnership to co-develop a game-changing solution for the administration of vaccines targeting a variety of emerging viruses. Kindeva has granted […]
Learn MoreKindeva Global Health Security donates ATNAA to Ukraine through the European Commission’s rescEU and Governmental Strategic Reserves Agency (RARS)
WOODBURY, Minn. and ST. LOUIS, Mo.; May 29, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection […]
Learn MoreKindeva Drug Delivery acquires Summit Biosciences, a specialized Nasal Drug Development and Manufacturing organization
WOODBURY, Minn., ST. LOUIS, Mo., LEXINGTON, Ky.; Jan. 18, 2024 (Business Wire) Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track […]
Learn MoreNutriband signs Commercial Development and Clinical Supply Agreement with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse deterrent fentanyl patch
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) […]
Learn MoreKindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) announce collaboration for Low GWP Propellant Conversion
WOODBURY, Minn. and St. LOUIS, Mo. and BOSTON; Dec. 5, 2023 – Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and […]
Learn MoreMeridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, awarded contract to supply DuoDote®
ST. LOUIS, Mo. and WOODBURY, Minn.; Nov. 14, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services. Meridian is […]
Learn MoreMeridian Medical Technologies, LLC, and the European Commission’s DG HERA sign agreement for 13 countries from the EEA to purchase Tecovirimat SIGA
ST. LOUIS, Mo. and WOODBURY, Minn.; Oct. 23, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority). As […]
Learn MoreViatris announces launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first FDA-approved generic version of Symbicort® for people with asthma and chronic obstructive pulmonary disease, in partnership with Kindeva
Launch demonstrates companies’ commitment to bringing complex generic medicines to the market to help increase patient access PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca’s Symbicort® with an Abbreviated […]
Learn MoreManufacturing more tomorrows
Partner with us and benefit from a team with technical expertise and a passion for purpose. As a true partner, strategically minded and dedicated to your lasting legacy, we provide customized solutions tailored to your precise requirements. From development to commercial manufacturing and beyond, our CDMO solutions are designed to help your product progress with purpose.
